The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. PharmaCyte Biotech Inc shares valued at $33,316 were purchased by Silverman Joshua on Jan 07 ’26. At $0.83 per share, Silverman Joshua acquired 40,000 shares. The insider’s holdings grew to 416,250 shares worth approximately $0.39 million following the completion of this transaction.
Also, Silverman Joshua purchased 30,000 shares, netting a total of over 23,667 in proceeds. Following the buying of shares at $0.79 each, the insider now holds 376,250 shares.
Before that, Silverman Joshua had added 30,000 shares to its account. In a trade valued at $23,493, the CEO and President bought PharmaCyte Biotech Inc shares for $0.78 each. Upon closing the transaction, the insider’s holdings increased to 30,000 shares, worth approximately $0.33 million.
Analyzing PMCB Stock Performance
On last trading session, PharmaCyte Biotech Inc [NASDAQ: PMCB] rose 2.33% to $0.94. The stock’s lowest price that day was $0.88, but it reached a high of $1.0 in the same session. During the last five days, there has been a surge of approximately 1.67%. Over the course of the year, PharmaCyte Biotech Inc shares have dropped approximately -38.80%.
Support And Resistance Levels for PharmaCyte Biotech Inc (PMCB)
RSI (Relative Strength Index) is 58.91 on the 14-day chart, showing neutral technical sentiment.
Is PharmaCyte Biotech Inc subject to short interest?
Stocks of PharmaCyte Biotech Inc saw a sharp steep in short interest on 2025-12-31 dropping by -0.86 million shares to 62893.0. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 0.93 million shares. A decline of -1371.67% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.01 of the overall float, the days-to-cover ratio (short ratio) decline to 0.01.
